Literature DB >> 319922

Multiclinic controlled trial of bethanidine and guanethidine in severe hypertension.

E A Ramirez, L Elson, A S Gear, J R Oster, F N Talmers, J R Thomas.   

Abstract

One hundred and eight patients with initial diastolic blood pressure in the range of 100-124 mm Hg while taking hydrochlorothiazide were assigned randomly and double-blind to hydrochlorothiazide plus either bethanidine or guanethidine. The average reduction of the fifth and sixth months' diastolic blood pressure was 18.4 mm Hg for guanethidine and 13.6 mm Hg for bethanidine (P less than 0.01). The distribution of the individual values was such that 68.8% of guanethidine treated patients achieved a diastolic level below 90 mm Hg, compared to only 45.5% of the bethanidine treated group (P less than 0.025). The degree of orthostatic fall in blood pressure was greater with bethanidine than with guanethidine (P less than 0.05). The diurnal variation of blood pressure was slightly greater with bethanidine than with guanethidine. The results significantly favor guanethidine. This study failed to demonstrate that the shorter action of bethanidine confers significantly better control of blood pressure than the longer action of guanethidine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 319922     DOI: 10.1161/01.cir.55.3.519

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  3 in total

1.  How useful is riboflavin as a tracer of medication compliance?

Authors:  I E Babiker; P R Cooke; M G Gillett
Journal:  J Behav Med       Date:  1989-02

2.  Riboflavin as a tracer of medication compliance.

Authors:  P M Dubbert; A King; S R Rapp; D Brief; J E Martin; M Lake
Journal:  J Behav Med       Date:  1985-09

3.  Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement.

Authors:  Abigail J Herron; John J Mariani; Martina Pavlicova; Christina M Parrinello; Krysten W Bold; Frances R Levin; Edward V Nunes; Maria A Sullivan; Wilfred N Raby; Adam Bisaga
Journal:  Drug Alcohol Depend       Date:  2012-08-22       Impact factor: 4.492

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.